Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...

Merck (MRK) on Friday said that the U.S. Food and Drug Administration (FDA) has approved its blockbuster drug Keytruda for ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...